Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Mark Lebwohl, MD Chairman, Department of Dermatology Mount Sinai School of Medicine New York, NY PowerPoint Presentation
Download Presentation
Mark Lebwohl, MD Chairman, Department of Dermatology Mount Sinai School of Medicine New York, NY

Mark Lebwohl, MD Chairman, Department of Dermatology Mount Sinai School of Medicine New York, NY

304 Vues Download Presentation
Télécharger la présentation

Mark Lebwohl, MD Chairman, Department of Dermatology Mount Sinai School of Medicine New York, NY

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Raptiva™ (efalizumab)Plaque Psoriasis: The Unmet Need Mark Lebwohl, MD Chairman, Department of DermatologyMount Sinai School of Medicine New York, NY

  2. Psoriasis

  3. Psoriasis

  4. Psoriasis

  5. Psoriasis: Unmet Medical Need • 4½ million Americans have psoriasis with at least 10% of those patients having moderate-to-severe disease • About 500-600,000 of these patients are candidates for systemic therapy • People with moderate-to-severe disease reported a larger, negative impact on QOL • Majority of patients with moderate-to-severe psoriasis are not using the most aggressive treatments for their disease Koo JY. Dermatol Clinics 1996;14:485-96., NPF Survey

  6. Short Form 36 (SF-36) Health Survey • Health status measurement tool that can compare different disease states • 8 domains • Assesses impact of disease and treatment on functional status and well-being • Physical Component Summary • Mental Component Summary Ware JE, et al. SF-36® Health Survey Manual and Interpretation Guide. The Health Institute;1993.

  7. Impact of Psoriasis vs. Other Diseases on Patient-reported Physical Outcomes 35 Congestive Heart Failure 41 Psoriasis 42 Diabetes 43 Myocardial Infarction SF-36 Score 43 Arthritis 44 Hypertension 45 Depression 45 Cancer 0 5 10 15 20 25 30 35 40 45 50 Physical Component Summary Score (n = 317) Lower scores reflect worse patient-reported outcomes Rapp SR, et al. J Am Acad Dermatol. 1999;41:401-407.

  8. Impact of Psoriasis vs. Other Diseases on Patient-reported Mental Outcomes 35 Depression 46 Psoriasis 49 Arthritis Cancer 49 SF-36 Score 50 Congestive Heart Failure 52 Diabetes 52 Hypertension 52 Myocardial Infarction 0 10 20 30 40 50 60 Mental Component Summary Score (n = 317) Lower scores reflect worse patient-reported outcomes Rapp SR, et al. J Am Acad Dermatol. 1999;41:401-407.

  9. 0 10 20 30 40 50 60 70 80 90 100 Patients Dissatisfied with Current Psoriasis Therapy Frustrated withtreatment 78% Treatment notaggressive enough 32% Percentage of respondents Krueger G, et al. Arch Dermatol. 2001;137:280-284.

  10. Drawbacks of Current Psoriasis Therapies

  11. Rotational Therapy • All widely used therapies have shortcomings • Major concerns with toxicities have resulted in “rotational therapy” as a management approach

  12. Concerns from a Practitioner • Concerns • Safety of the current treatments for moderate-to-severe plaque psoriasis • Needs • Need for safe, convenient and effective treatment option that reduces psoriasis • Need for a therapy safe enough to give over the long term • Need for rapid acting therapy

  13. Efficacy of Methotrexate Treatment (15–30 mg/wk): PASI Response at Week 24 n = 23 Proportion responding (%)  50% Reduction in PASI  90% Reduction in PASI  75% Reductionin PASI Callis et al. Presented at: 63rd Annual Meeting of the Society for Investigative Dermatology; May 15-18, 2002, Los Angeles, CA

  14. Example: PASI-50 After 12 Weeks of Treatment Day 0: PASI 18.0 Day 84: PASI 6.8(62% improvement) Study 2390, #35006

  15. Summary • Psoriasis is a chronic life-long disease that causes significant disability • Current treatments have limitations • Need a safe and effective therapy for long-term use